DGIdb - MITOXANTRONE Drug Record

MITOXANTRONE chembl:CHEMBL58 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MITOXANTRONE
NSC-279836
MITOXANTRONE HCL
NOVANTRONE
CL-232315
MITOXANTRONUM
NOVANTRONE®
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
MITOXANTRONA
pubchem.compound:4212
drugbank:01204
rxcui:7005
chembl:CHEMBL58
chemidplus:65271-80-9

Drug Info:

Drug Categories	anthraquinones
Drug Categories	anthracenes
Drug Class	antineoplastic agents
Year of Approval	1987
Drug Class	Small molecule
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	cytochrome p-450 cyp2e1 inducers
Drug Categories	cytochrome p-450 cyp2e1 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2e1 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	p-glycoprotein inducers
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein substrates with narrow therapeutic index

(5 More Sources)

Publications:

Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
Mao et al., 1999, Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity., Biochemistry
Satherley et al., 2000, Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma., J. Pathol.
Ko et al., 2008, Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis., J. Neurol. Sci.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Takeda et al., 1998, A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide., Int. J. Hematol.
McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
Wang et al., 2001, Atp-bound topoisomerase ii as a target for antitumor drugs., J. Biol. Chem.
Brown et al., 1998, Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease., Am. J. Clin. Pathol.
Chi et al., 2001, A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer., Clin. Cancer Res.
Wan X et al., 2013, A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling., J Med Chem
List et al., 1996, Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia., Blood
Kobylinska et al., 2004, Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells., Oncol. Rep.
Rassidakis et al., 2002, BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome., Clin. Cancer Res.
Parker et al., Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells., Cancer Biol. Ther.
Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
Burchell et al., 1990, The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells., Int. Symp. Princess Takamatsu Cancer Res. Fund
Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics

MITOXANTRONE C10ORF67

Interaction Score: 2.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
MITOXANTRONE GALNT14

Interaction Score: 1.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31611591 21635146

Sources:
PharmGKB
MITOXANTRONE RPSA

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8630412

Sources:
NCI
MITOXANTRONE UGT1A5

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1966888

Sources:
NCI
MITOXANTRONE TOP2A

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10451375 11004693 18687447 11752352 9631585 9494516 11278845 9426516

Sources:
NCI TEND TdgClinicalTrial DrugBank GuideToPharmacology
MITOXANTRONE MBNL1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE DNMT1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12878861

Sources:
NCI
MITOXANTRONE BAX

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14767525 11839668

Sources:
NCI
MITOXANTRONE NSD2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE ARSA

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE PIM1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23442188

Sources:
DTC
MITOXANTRONE BCL2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11751483

Sources:
NCI
MITOXANTRONE SLCO1B1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398

Sources:
PharmGKB
MITOXANTRONE TOP2B

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
MITOXANTRONE BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12684687

Sources:
NCI
MITOXANTRONE ABCG2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
MITOXANTRONE RACGAP1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE THPO

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE WRN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE RAD52

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE NFKB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE RGS4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE BLM

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE MPHOSPH8

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE MAPK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE RECQL

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE POLH

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE HTT

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE FEN1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE YES1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE POLI

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE SMAD3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MITOXANTRONE POLK

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE ATAD5

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE KDM4A

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MITOXANTRONE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB01204

Version: 5.1.7

Alternate Names:

MITOXANTRONE DrugBank Drug Name

65271-80-9 CAS Number

Mitoxantrone Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Mazerski et al., 1998, The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations., Acta Biochim. Pol.

Hajihassan et al., 2009, Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins., J. Biomed. Sci.

Mao et al., 1999, Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity., Biochemistry

TEND: MITOXANTRONE
- Version: 01-August-2011
Alternate Names:

MITOXANTRONE Primary Drug Name

Drug Info:

Year of Approval 1987

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: MITOXANTRONE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:
DTC: MITOXANTRONE
- Version: 02-September-2020
Alternate Names:

CHEMBL58 ChEMBL Drug ID

Drug Info:

Publications:

Wan X et al., 2013, A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling., J Med Chem

NCI: MITOXANTRONE

Version: 14-September-2017

Alternate Names:

C665 NCI drug code

Drug Info:

Publications:

Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.

Parker et al., Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells., Cancer Biol. Ther.

List et al., 1996, Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia., Blood

PharmGKB: mitoxantrone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J

Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics

GuideToPharmacology: 178103816
- Version: 29-September-2020
Alternate Names:

MITOXANTRONE GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Mitoxantrone
- Version: 2020.06.01
Alternate Names:

D0R3JB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL58
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

MITOXANTRONE	DrugBank Drug Name
65271-80-9	CAS Number
Mitoxantrone	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

MITOXANTRONE Drug Record

MITOXANTRONE chembl:CHEMBL58 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31611591 21635146

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8630412

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1966888

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 10451375 11004693 18687447 11752352 9631585 9494516 11278845 9426516

Sources: NCI TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12878861

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14767525 11839668

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23442188

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11751483

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26663398

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12684687

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31611591 21635146

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8630412

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1966888

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
10451375 11004693 18687447 11752352 9631585 9494516 11278845 9426516

Sources:
NCI TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
12878861

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14767525 11839668

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23442188

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11751483

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26663398

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
12684687

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a